Sulfatase modifying factor 2 as a predictive biomarker for urothelial carcinoma
Abstract Sulfatases mediate the sulfation level of cell-surface heparan sulfates to regulate signal transduction, thereby promoting cancer progression. Sulfatase activation requires a sulfatase modifying factor (SUMF) for the modification of its catalytic domain. The role of the SUMF family in uroth...
Saved in:
Main Authors: | Wei-Ting Kuo, Yi-Chen Lee, Jia-Bin Liao, Ching-Jiunn Tseng, Yi-Fang Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2025-02-01
|
Series: | Discover Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1007/s12672-025-01859-y |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pathological features and immunohistochemical characteristics of clear cell (glycogen-rich) urothelial carcinoma: a case report and systematic review of the literature
by: Weiming Wang, et al.
Published: (2025-02-01) -
Distribution and clinicopathological characteristics of G-CSF expression in tumor cells and stromal cells in upper tract urothelial carcinoma
by: Go Kobayashi, et al.
Published: (2024-12-01) -
FAN score predicts prognosis after platinum-based first-line chemotherapy in patients with metastatic urothelial carcinoma
by: Yu Ishizuya, et al.
Published: (2025-02-01) -
Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherapy: a meta-analysis
by: Weiming Liang, et al.
Published: (2025-02-01) -
Clinical and molecular analysis of JCPyV and BKPyV infection and associated risk of urothelial carcinoma development in the upper tract
by: Chun-Nun Chao, et al.
Published: (2025-02-01)